The Soft Tissue Allografts market is anticipated to grow from US$ 4.08 billion in 2024 and is projected to reach US$ 6.74 billion by 2031; it is expected to register a CAGR of 7.4% during 2025-2031. Increasing aging population and the rising incidence of sports injuries & trauma are contributing to the growing soft tissue allografts market size. However, the high cost of procedures hampers the soft tissue allografts market growth. Further, development of customized grafts is expected to bring in new soft tissue allografts market trends in the coming years.
In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for soft tissue allografts in the world.
Sports injuries often lead to ailments such as joint pain, stiffness, and swelling. As per the data published by Johns Hopkins, there has been a significant rise in the number of participants in organized sports activities over the years. Approximately 30 million children and adolescents participate in youth sports in the country, leading to an increase in the number of sports injuries among young athletes, with over 3.5 million injuries reported yearly. Almost one-third of all injuries that occur in childhood are caused by sports.
According to the National Safety Council (NSC), biking caused 426,000 injuries in 2020, the most of any sport or recreational activity, while exercises (with or without equipment) ranked second with ~378,000 injuries. These factors were followed by off-highway vehicles (OHVs, including mopeds and minibikes) with 230,000 injuries, and skateboards, scooters, and hoverboards with 218,000 injuries. Sports-related injuries often involve damage to soft tissues such as muscles, tendons, and ligaments. These injuries range from strains and sprains to more severe conditions such as tears or ruptures.
In some cases, when the injury is too extensive for the body to heal on its own, soft tissue allografts are used to repair or reconstruct the damaged tissue. These allografts are particularly useful for repairing ligaments, tendons, or cartilages that are too damaged to treat via other methods such as sutures or autografts (using patient's self-tissue).
The US represents a significant portion of the soft tissue allografts market, with a notable number of procedures performed annually. According to a study titled “New Device Inspired by Python Teeth Doubles Strength of Rotator Cuff,” published in 2024, more than 600,000 rotator cuff procedures are performed yearly in the US. As per the American Orthopedic Society for Sports Medicine, nearly 100,000 to 250,000 ACL ruptures are reported in the country annually. Several tissue injuries have received significant importance, increasing awareness about soft tissue injuries and their treatment among athletes.
Furthermore, in May 2023, AlloSource announced the introduction of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution designed for soft tissue reconstruction. It is one of the largest nonprofit providers of allografts in the US, known for developing innovative cellular and tissue products to aid surgeons in healing their patients. ADM was developed to assist surgeons in repairing and reconstructing soft tissue defects, offering long-term structural support.
This deep reticular dermal allograft integrates with the surrounding tissue, serving as a scaffold that encourages cell repopulation and regeneration of natural host tissues. Its flexible and pliable characteristics make it ideal for various medical procedures that demand strength and biocompatibility in a human regenerative tissue matrix, allowing for precision placement and optimal handling.
Soft Tissue Allografts Market Analysis
New Product Launches to Provide Market Opportunities in Future
Several companies are focusing on developing innovative products through extensive research. These products are likely to offer superior treatment outcomes compared to the existing products. For instance, AlloSource is one of the largest allograft providers in the US, offering innovative cellular and tissue products to help healthcare providers heal their patients. In May 2023, the company announced the launch of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction. In June 2024, Axogen, Inc., a global leader in developing innovative surgical solutions for peripheral nerve injuries, announced the launch of its new product named Avive+ Soft Tissue Matrix.
This product is intended for use as a soft tissue barrier; it is a resorbable, multi-layer amniotic membrane allograft designed to provide temporary protection and tissue separation during the critical phase of peripheral nerve healing. In February 2022, Amnio Technology, a global leader in amniotic tissue allograft development and distribution, announced the launch of two new products in its PalinGen membrane line: the PalinGen Dual-Layer Membrane and the Dual Layer PalinGen X-Membrane.
Similar to all products in the PalinGen family, these new allografts are minimally modified and are intended for homologous use. The new soft tissue allograft products launched in recent years are designed to meet changing patient needs, improve recovery times, reduce complications, and address various clinical indications. Launching more such products is expected to create significant growth opportunities for the soft tissue allograft market in the coming years.
Soft Tissue Allografts Market Report Segmentation Analysis
Key segments that contributed to the derivation of the soft tissue allografts market analysis are type, application, and end user.
Zimmer Biomet Holdings Inc, Conmed Corp, Stryker Corp, Smith & Nephew Plc, Integra LifeSciences Holdings Corp, Arthrex Inc, AbbVie Inc, Organogenesis Inc., Dentsply Sirona Inc, and Axogen Corporation are among the key companies operating in the soft tissue allografts market.
The National Health Service (NHS), American Academy of Orthopaedic Surgeons (AAOS), World Health Organization, US Department of Health and Human Services, and National Safety Council are among the primary and secondary sources referred to while preparing the soft tissue allografts market report.
In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for soft tissue allografts in the world.
Sports injuries often lead to ailments such as joint pain, stiffness, and swelling. As per the data published by Johns Hopkins, there has been a significant rise in the number of participants in organized sports activities over the years. Approximately 30 million children and adolescents participate in youth sports in the country, leading to an increase in the number of sports injuries among young athletes, with over 3.5 million injuries reported yearly. Almost one-third of all injuries that occur in childhood are caused by sports.
According to the National Safety Council (NSC), biking caused 426,000 injuries in 2020, the most of any sport or recreational activity, while exercises (with or without equipment) ranked second with ~378,000 injuries. These factors were followed by off-highway vehicles (OHVs, including mopeds and minibikes) with 230,000 injuries, and skateboards, scooters, and hoverboards with 218,000 injuries. Sports-related injuries often involve damage to soft tissues such as muscles, tendons, and ligaments. These injuries range from strains and sprains to more severe conditions such as tears or ruptures.
In some cases, when the injury is too extensive for the body to heal on its own, soft tissue allografts are used to repair or reconstruct the damaged tissue. These allografts are particularly useful for repairing ligaments, tendons, or cartilages that are too damaged to treat via other methods such as sutures or autografts (using patient's self-tissue).
The US represents a significant portion of the soft tissue allografts market, with a notable number of procedures performed annually. According to a study titled “New Device Inspired by Python Teeth Doubles Strength of Rotator Cuff,” published in 2024, more than 600,000 rotator cuff procedures are performed yearly in the US. As per the American Orthopedic Society for Sports Medicine, nearly 100,000 to 250,000 ACL ruptures are reported in the country annually. Several tissue injuries have received significant importance, increasing awareness about soft tissue injuries and their treatment among athletes.
Furthermore, in May 2023, AlloSource announced the introduction of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution designed for soft tissue reconstruction. It is one of the largest nonprofit providers of allografts in the US, known for developing innovative cellular and tissue products to aid surgeons in healing their patients. ADM was developed to assist surgeons in repairing and reconstructing soft tissue defects, offering long-term structural support.
This deep reticular dermal allograft integrates with the surrounding tissue, serving as a scaffold that encourages cell repopulation and regeneration of natural host tissues. Its flexible and pliable characteristics make it ideal for various medical procedures that demand strength and biocompatibility in a human regenerative tissue matrix, allowing for precision placement and optimal handling.
Soft Tissue Allografts Market Analysis
New Product Launches to Provide Market Opportunities in Future
Several companies are focusing on developing innovative products through extensive research. These products are likely to offer superior treatment outcomes compared to the existing products. For instance, AlloSource is one of the largest allograft providers in the US, offering innovative cellular and tissue products to help healthcare providers heal their patients. In May 2023, the company announced the launch of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction. In June 2024, Axogen, Inc., a global leader in developing innovative surgical solutions for peripheral nerve injuries, announced the launch of its new product named Avive+ Soft Tissue Matrix.
This product is intended for use as a soft tissue barrier; it is a resorbable, multi-layer amniotic membrane allograft designed to provide temporary protection and tissue separation during the critical phase of peripheral nerve healing. In February 2022, Amnio Technology, a global leader in amniotic tissue allograft development and distribution, announced the launch of two new products in its PalinGen membrane line: the PalinGen Dual-Layer Membrane and the Dual Layer PalinGen X-Membrane.
Similar to all products in the PalinGen family, these new allografts are minimally modified and are intended for homologous use. The new soft tissue allograft products launched in recent years are designed to meet changing patient needs, improve recovery times, reduce complications, and address various clinical indications. Launching more such products is expected to create significant growth opportunities for the soft tissue allograft market in the coming years.
Soft Tissue Allografts Market Report Segmentation Analysis
Key segments that contributed to the derivation of the soft tissue allografts market analysis are type, application, and end user.
- Based on type, the soft tissue allografts market is segmented into cartilage allograft, tendon allograft, dental allograft, meniscus allografts, placental tissue, and others. The cartilage allograft segment held the largest share of the market in 2024.
- In terms of application, the soft tissue allografts market is categorized into orthopedic, dentistry, wound care, and others. The orthopedic segment dominated the market in 2024.
- In terms of end user, the soft tissue allografts market is categorized into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2024.
Zimmer Biomet Holdings Inc, Conmed Corp, Stryker Corp, Smith & Nephew Plc, Integra LifeSciences Holdings Corp, Arthrex Inc, AbbVie Inc, Organogenesis Inc., Dentsply Sirona Inc, and Axogen Corporation are among the key companies operating in the soft tissue allografts market.
The National Health Service (NHS), American Academy of Orthopaedic Surgeons (AAOS), World Health Organization, US Department of Health and Human Services, and National Safety Council are among the primary and secondary sources referred to while preparing the soft tissue allografts market report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the soft tissue allografts market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the soft tissue allografts market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Soft Tissue Allografts Market Landscape
5. Soft Tissue Allografts Market - Key Market Dynamics
6. Soft Tissue Allografts Market - Global Market Analysis
7. Soft Tissue Allografts Market Analysis - by Type
8. Soft Tissue Allografts Market Analysis - by Application
9. Soft Tissue Allografts Market Analysis - by End User
10. Soft Tissue Allografts Market - Geographical Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the Soft Tissue Allografts Market include:- Stryker Corp
- Smith & Nephew Plc
- Integra LifeSciences Holdings Corp
- Arthrex Inc
- AbbVie Inc
- Organogenesis Inc.
- Dentsply Sirona Inc
- Axogen Corporation
- Zimmer Biomet Holdings Inc
- Conmed Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 165 |
| Published | March 2025 |
| Forecast Period | 2024 - 2031 |
| Estimated Market Value ( USD | $ 4.08 Billion |
| Forecasted Market Value ( USD | $ 6.74 billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
